Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. Europe Oral Antibiotics Market, 2019-2030, $ mn 20
Figure 6. Impact of COVID-19 on Business 21
Figure 7. Primary Drivers and Impact Factors of Europe Oral Antibiotics Market 23
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 26
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 26
Figure 10. Primary Restraints and Impact Factors of Europe Oral Antibiotics Market 27
Figure 11. Investment Opportunity Analysis 31
Figure 12. Porter’s Fiver Forces Analysis of Europe Oral Antibiotics Market 34
Figure 13. Breakdown of Europe Oral Antibiotics Market by Drug Class, 2019-2030, % of Revenue 39
Figure 14. Europe Addressable Market Cap in 2020-2030 by Drug Class, Value ($ mn) and Share (%) 39
Figure 15. Europe Oral Antibiotics Market: Cephalosporin, 2019-2030, $ mn 40
Figure 16. Europe Oral Antibiotics Market: Penicillin, 2019-2030, $ mn 42
Figure 17. Europe Oral Antibiotics Market: Macrolides, 2019-2030, $ mn 43
Figure 18. Europe Oral Antibiotics Market: Tetracycline, 2019-2030, $ mn 44
Figure 19. Europe Oral Antibiotics Market: Quinolones, 2019-2030, $ mn 45
Figure 20. Europe Oral Antibiotics Market: Sulfonamides, 2019-2030, $ mn 46
Figure 21. Europe Oral Antibiotics Market: Aminoglycosides, 2019-2030, $ mn 47
Figure 22. Europe Oral Antibiotics Market: Other Drug Classes, 2019-2030, $ mn 48
Figure 23. Breakdown of Europe Oral Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue 50
Figure 24. Europe Addressable Market Cap in 2020-2030 by Action Mechanism, Value ($ mn) and Share (%) 50
Figure 25. Europe Oral Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, $ mn 51
Figure 26. Europe Oral Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, $ mn 52
Figure 27. Europe Oral Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, $ mn 53
Figure 28. Europe Oral Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, $ mn 54
Figure 29. Europe Oral Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, $ mn 55
Figure 30. Europe Oral Antibiotics Market: Other Mechanisms, 2019-2030, $ mn 56
Figure 31. Breakdown of Europe Oral Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue 58
Figure 32. Europe Addressable Market Cap in 2020-2030 by Drug Origin, Value ($ mn) and Share (%) 58
Figure 33. Europe Oral Antibiotics Market: Natural Antibiotics, 2019-2030, $ mn 59
Figure 34. Europe Oral Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, $ mn 60
Figure 35. Europe Oral Antibiotics Market: Synthetic Antibiotics, 2019-2030, $ mn 61
Figure 36. Breakdown of Europe Oral Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue 63
Figure 37. Europe Addressable Market Cap in 2020-2030 by Activity Spectrum, Value ($ mn) and Share (%) 63
Figure 38. Europe Oral Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, $ mn 64
Figure 39. Europe Oral Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, $ mn 65
Figure 40. Breakdown of Europe Oral Antibiotics Market by Application, 2019-2030, % of Revenue 67
Figure 41. Europe Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 67
Figure 42. Europe Oral Antibiotics Market: Urinary Tract Infections (UTIS), 2019-2030, $ mn 68
Figure 43. Europe Oral Antibiotics Market: Dental Infections, 2019-2030, $ mn 69
Figure 44. Europe Oral Antibiotics Market: Monotherapies for Dental Infections, 2019-2030, $ mn 70
Figure 45. Europe Oral Antibiotics Market: Combined Therapies for Dental Infections, 2019-2030, $ mn 71
Figure 46. Europe Oral Antibiotics Market: Respiratory Tract Infections (RTIS), 2019-2030, $ mn 72
Figure 47. Europe Oral Antibiotics Market: Upper Respiratory Tract Infections (URTI), 2019-2030, $ mn 73
Figure 48. Europe Oral Antibiotics Market: Lower Respiratory Tract Infections (LRTIs), 2019-2030, $ mn 74
Figure 49. Europe Oral Antibiotics Market: Other Applications, 2019-2030, $ mn 75
Figure 50. Breakdown of Europe Oral Antibiotics Market by Drug Type, 2019-2030, % of Revenue 76
Figure 51. Europe Addressable Market Cap in 2020-2030 by Drug Type, Value ($ bn) and Share (%) 77
Figure 52. Europe Oral Antibiotics Market: Brand Antibiotics, 2019-2030, $ bn 78
Figure 53. Europe Oral Antibiotics Market: Generic Antibiotics, 2019-2030, $ bn 79
Figure 54. Breakdown of European Oral Antibiotics Market by Country, 2019 and 2030, % of Revenue 81
Figure 55. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 82
Figure 56. Oral Antibiotics Market in Germany, 2019-2030, $ bn 83
Figure 57. Oral Antibiotics Market in UK, 2019-2030, $ bn 85
Figure 58. Oral Antibiotics Market in France, 2019-2030, $ bn 88
Figure 59. Oral Antibiotics Market in Spain, 2019-2030, $ bn 90
Figure 60. Oral Antibiotics Market in Italy, 2019-2030, $ bn 92
Figure 61. Oral Antibiotics Market in Russia, 2019-2030, $ bn 94
Figure 62. Oral Antibiotics Market in Rest of Europe, 2019-2030, $ bn 96
Figure 63. Growth Stage of Europe Oral Antibiotics Industry over the Forecast Period 98
Europe oral antibiotics market accounted for $4,612.4 million in 2019 and will grow by 3.8% annually over 2020-2030 owing to the rising infection complications associated with COVID-19 epidemic, development of innovative antibiotics, and growing healthcare expenditure. Highlighted with 38 tables and 63 figures, this 128-page report “Europe Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe oral antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe oral antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country. Based on Drug Class, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Cephalosporin • Cefuroxime Axetil • Cephalexin • Cefixime • Cefpodoxime • Other Cephalosporin Penicillin Macrolides Tetracycline Quinolones Sulfonamides Aminoglycosides Other Drug Classes Based on Action Mechanism, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Cell Wall Synthesis Inhibitors • Mycolic Acid Inhibitors • RNA Synthesis Inhibitors • DNA Synthesis Inhibitors • Protein Synthesis Inhibitors • Other Mechanisms Based on Drug Origin, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Natural Antibiotics • Semi-synthetic Antibiotics • Synthetic Antibiotics Based on Activity Spectrum, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Broad-spectrum Antibiotics • Narrow-spectrum Antibiotics Based on Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Urinary Tract Infections (UTIS) • Upper Respiratory Tract Infections (URTI) • Lower Respiratory Tract Infections (LRTIs) Dental Infections • Monotherapies • Combined Therapies Respiratory Tract Infections (RTIS) Other Applications Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Brand Antibiotics • Generic Antibiotics Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Europe oral antibiotics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Astellas Pharma AstraZeneca Plc Bayer AG Bristol Myers Squibb Company Cipla Inc. Dr. Reddy’s Laboratories Ltd. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. GlaxoSmithKline plc. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) Mayne Pharma Group Ltd. MELINTA THERAPEUTICS, INC. Merck KGaA Novartis AG Pfizer Inc. Sanofi Sun Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More